KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.99

An evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal.

Tiffany Foo, Tharani Krishnan, Niall Tebbutt, Timothy Price, Christos Karapetis, Amitesh Roy

Expert Rev Anticancer Ther 1-7

PMID42483956
PMCID-
DOI10.1080/14737140.2026.2708761
发表日期2026-07-22
入排依据:记录类型属于综述、Meta 分析、社论、评论、病例或指南。
摘要

摘要

INTRODUCTION: Anal squamous cell carcinoma (SCC) is a rare cancer. Metastatic anal SCC is still a significant clinical challenge due to limited treatment options and poor outcomes. AREAS COVERED: This review paper will focus on retifanlimab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) pathway, and its role in the treatment of metastatic anal SCC, both as monotherapy or in combination with chemotherapy. This review will evaluate its efficacy, safety, and place within the current therapeutic landscape. EXPERT OPINION: The POD1UM-303 trial is the first randomized phase III study for patients with metastatic and locally, advanced unresectable anal SCC. The results from POD1UM-303 are practice-changing, establishing retifanlimab in combination with carboplatin and paclitaxel as a new standard of care for first-line treatment in this setting. Current research includes investigating earlier integration of PD-(L)1 inhibitors with definitive chemoradiotherapy in the locally advanced setting. Further biomarker-driven studies are essential to guide treatment and improve patient selection.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。